PB 6 of 2016
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 1)
National Health Act 1953
___________________________________________________________________________
I, Tony Wynd, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated 29 January 2016
TONY WYND
Acting Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________
1 Name of Instrument
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2016 (No. 1).
(2) This Instrument may also be cited as PB 6 of 2016.
2 Commencement
This Instrument commences on 1 February 2016.
3 Amendments to PB 79 of 2011
Amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
Amendments
[1] Schedule 1 Part 1 entry for Docetaxel:
omit:
Solution concentrate for I.V. infusion 20 mg in 1 mL
Injection
Taxotere
SW
MP
D
[2] Schedule 1 Part 1 entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 4 mL:
omit:
Taxotere
SW
MP
D
[3] Schedule 1 Part 1 entry for Oxaliplatin in each of the forms Solution concentrate for I.V. infusion 100 mg in 20 mL; Solution concentrate for I.V. infusion 200 mg in 40 mL; Solution concentrate for I.V. infusion 50 mg in 10 mL:
omit:
Eloxatin
SW
MP
D
[4] Schedule 1 Part 1 entry for Pemetrexed:
substitute:
Pemetrexed
Powder for I.V. infusion 100 mg (as disodium heptahydrate)
Injection
Alimta
LY
MP
C4789 C4792
D
DBL Pemetrexed
HH
MP
C4789 C4792
D
Pemetrexed APOTEX
TX
MP
C4789 C4792
D
Pemetrexed Juno
JU
MP
C4789 C4792
D
Pemetrexed MYX
YN
MP
C4789 C4792
D
Reladdin
AF
MP
C4789 C4792
D
Powder for I.V. infusion 500 mg (as disodium heptahydrate)
Injection
Alimta
LY
MP
C4789 C4792
D
DBL Pemetrexed
HH
MP
C4789 C4792
D
Pemetrexed APOTEX
TX
MP
C4789 C4792
D
Pemetrexed DRLA
RZ
MP
C4789 C4792
D
Pemetrexed Juno
JU
MP
C4789 C4792
D
Pemetrexed MYX
YN
MP
C4789 C4792
D
Pemetrexed Sandoz
SZ
MP
C4789 C4792
D
Reladdin
AF
MP
C4789 C4792
D
[5] Schedule 3 after entry for JC:
insert:
JU
Juno Pharmaceuticals Pty Ltd
55 156 303 650
